123 related articles for article (PubMed ID: 27760946)
1. [Novel HER2-Targeted Therapy Combined with Gold Nanoparticles].
Kubota T; Kuroda S; Morihiro T; Tazawa H; Kagawa S; Fujiwara T
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1237-1239. PubMed ID: 27760946
[TBL] [Abstract][Full Text] [Related]
2. HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer.
Kubota T; Kuroda S; Kanaya N; Morihiro T; Aoyama K; Kakiuchi Y; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
Nanomedicine; 2018 Aug; 14(6):1919-1929. PubMed ID: 29885899
[TBL] [Abstract][Full Text] [Related]
3. [Novel Therapeutic Strategy for Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer].
Kanaya N; Kuroda S; Kubota T; Morihiro T; Kikuchi S; Nishizaki M; Tazawa H; Kagawa S; Fujiwara T
Gan To Kagaku Ryoho; 2017 Oct; 44(10):883-885. PubMed ID: 29066684
[TBL] [Abstract][Full Text] [Related]
4. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.
Oshima Y; Tanaka H; Murakami H; Ito Y; Furuya T; Kondo E; Kodera Y; Nakanishi H
Gastric Cancer; 2014; 17(3):450-62. PubMed ID: 23948998
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin- and Trastuzumab-Modified Gold Nanoparticles as Potential Multimodal Agents for Targeted Therapy of HER2+ Cancers.
Żelechowska-Matysiak K; Wawrowicz K; Wierzbicki M; Budlewski T; Bilewicz A; Majkowska-Pilip A
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985421
[TBL] [Abstract][Full Text] [Related]
7. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
[TBL] [Abstract][Full Text] [Related]
8. Improvement of the Effectiveness of HER2+ Cancer Therapy by Use of Doxorubicin and Trastuzumab Modified Radioactive Gold Nanoparticles.
Żelechowska-Matysiak K; Salvanou EA; Bouziotis P; Budlewski T; Bilewicz A; Majkowska-Pilip A
Mol Pharm; 2023 Sep; 20(9):4676-4686. PubMed ID: 37607353
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab Rechallenge After Lapatinib- and Trastuzumab-Resistant Disease Progression in HER2-Positive Breast Cancer.
Araki K; Fukada I; Horii R; Takahashi S; Akiyama F; Iwase T; Ito Y
Clin Breast Cancer; 2015 Dec; 15(6):432-9. PubMed ID: 26232059
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab-modified DM1-loaded nanoparticles for HER2
Rong L; Zhou S; Liu X; Li A; Jing T; Liu X; Zhang Y; Cai S; Tang X
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1708-1718. PubMed ID: 29069935
[TBL] [Abstract][Full Text] [Related]
11. Design and characterization of HER-2-targeted gold nanoparticles for enhanced X-radiation treatment of locally advanced breast cancer.
Chattopadhyay N; Cai Z; Pignol JP; Keller B; Lechtman E; Bendayan R; Reilly RM
Mol Pharm; 2010 Dec; 7(6):2194-206. PubMed ID: 20973534
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab decorated methotrexate-human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells.
Taheri A; Dinarvand R; Atyabi F; Ghahremani MH; Ostad SN
Eur J Pharm Sci; 2012 Sep; 47(2):331-40. PubMed ID: 22771547
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
Barok M; Tanner M; Köninki K; Isola J
Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
[TBL] [Abstract][Full Text] [Related]
14. Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers.
Rao Y; Samuels Z; Carter LM; Monette S; Panikar SS; Pereira PMR; Lewis JS
Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2220413120. PubMed ID: 36972439
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
16. [Predictive diagnosis of HER2 in gastric adenocarcinoma].
Daum O; Skálová A; Rozkos T; Laco J
Cesk Patol; 2011 Oct; 47(4):160-3. PubMed ID: 22145214
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
[TBL] [Abstract][Full Text] [Related]
18. Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms.
Ito K; Mitsunaga M; Arihiro S; Saruta M; Matsuoka M; Kobayashi H; Tajiri H
BMC Cancer; 2016 Jan; 16():37. PubMed ID: 26810644
[TBL] [Abstract][Full Text] [Related]
19. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
